MARKETS / NASDAQ / MBOT
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Microbot Medical Inc. MBOT

17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.29
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-32.4%
Net margin · FY25
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
Revenue, FY2025 · full 17-year series below
Revenue Net income
0.00040.00080.00120.0016-0.02009201220152018202120242025
0.00040.00080.00120.0016-0.02016201920222025

Per share
USD -0.29
Diluted EPS, FY2025
EPS
0.40.81.2-0.292009201220152018202120242025
0.40.81.2-0.292016201920222025

The company pays no cash dividend.

Profitability
-32.4%
Return on equity, FY2025
ROE
0.250.50.751-32.4%2009201220152018202120242025
0.250.50.751-32.4%2016201920222025
Operating margin
Net margin
Return on assets-30.0%

Each USD of equity lost 32 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
−39.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−56.0%
−39.4%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.07B
Shares outstanding, FY2025
0.010.072009201220152018202120242025
0.020.072016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 81.5M
total assets, end of FY2025
Total assetsUSD 81.5M
EquityUSD 77.6M
CashUSD 3.9M
Current ratio23.33×

Equity funds 95% of total assets.

History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
0.0
0.0
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.29
−0.73
−1.05
−1.81
−1.59
−1.29
−1.70
−2.41
−2.76
0.40
0.04
−0.53
−0.61
−0.99
−1.50
−2.05
−2.55
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−32.4
−285.0
−182.2
−121.5
−58.5
−32.8
−44.1
−128.2
−129.9
−1184.2
−232.3
−414.2
−182.7
−230.6
−162.8
−109.8
−88.6
Shares out B
0.07
0.02
0.01
0.01
0.01
0.01
0.01
0.00
0.00
0.02
0.01
0.07
0.06
0.04
0.02
0.01
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
52 of 53
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 1 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed